Do Not Stop Aspirin for PEG Insertion
Aspirin should be continued during PEG insertion, regardless of whether the patient is on low-dose or higher-dose aspirin therapy. PEG is classified as a high-risk endoscopic procedure, but current guidelines explicitly recommend continuing aspirin even for high-risk procedures 1.
Evidence-Based Reasoning
The 2021 BSG/ESGE guidelines provide clear direction on this matter. While PEG is categorized as a high-risk bleeding procedure (alongside polypectomy, EMR/ESD, and variceal therapy), the guidelines make a critical distinction based on the patient's thrombotic risk profile 1:
For Patients at High Thrombotic Risk
- Continue aspirin (strong recommendation, high quality evidence)
- High thrombotic risk includes:
- Ischemic heart disease without coronary stent
- Cerebrovascular disease
- Peripheral vascular disease
- Coronary stents (especially within 6-12 months of drug-eluting stent or >1 month of bare metal stent)
For Patients at Low Thrombotic Risk
- Continue aspirin (strong recommendation, low quality evidence)
- The guidelines do not recommend stopping aspirin even in this lower-risk group
Supporting Research Evidence
Real-world data strongly supports this approach. A large retrospective study of 990 PEG procedures found no association between aspirin use (at any dose) and post-PEG bleeding 2. Another study of 1,541 PEG procedures reported only 0.4% bleeding directly attributed to PEG, with aspirin not identified as a predictor of bleeding 3.
Importantly, one study demonstrated that PEG using the pull method was safe even in patients on dual antiplatelet therapy (DAPT), with minimal bleeding complications 4.
Critical Distinction: P2Y12 Inhibitors vs. Aspirin
Do not confuse aspirin management with P2Y12 inhibitor management. The guidelines clearly differentiate:
- P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor): Stop 7 days before PEG in low thrombotic risk patients 1
- Aspirin: Continue regardless of thrombotic risk
- DAPT patients: Continue aspirin, discuss P2Y12 inhibitor cessation with interventional cardiology 1
Post-Procedure Management
Resume any temporarily discontinued antiplatelet therapy 1-2 days after the procedure, depending on perceived hemorrhagic and thrombotic risks (strong recommendation, moderate quality evidence) 1.
Common Pitfalls to Avoid
- Do not stop aspirin "to be safe" - The thrombotic risk of aspirin cessation outweighs the minimal bleeding risk during PEG
- Do not apply the same rules to all antiplatelets - P2Y12 inhibitors require different management than aspirin
- Do not delay cardiology consultation - For patients with recent coronary stents on DAPT, involve interventional cardiology early in decision-making
- Watch for SSRIs - Serotonin reuptake inhibitors administered within 24 hours before PEG were associated with 4-fold increased bleeding risk (adjusted OR 4.1,95% CI 1.1-13.4) 2, which is a stronger predictor than aspirin
Bottom Line
The answer to "how long to stop aspirin" is: don't stop it. Continue aspirin through PEG insertion based on strong guideline recommendations and supporting research showing no increased bleeding risk with aspirin continuation.